Beijing Mandates Millions Must Get China-Made COVID-19 Vaccine as Testing Continues

An exhibition of SARS-CoV-2 Vaccine (Vero Cell) inactivated vaccines developed by Wuhan Biological Products Institute, subsidiary of Sinopharm Group’s China National Biotec Group (CNBG), during the Second World Health Expo that was held in Wuhan, China on Nov. 13, 2020. Getty Images

The Chinese regime recently mandated that 50 million doses of COVID-19 vaccines must be administered to people designated as high risk by Feb. 15, 2021—although drug companies have yet to complete testing and the vaccines have yet to be approved by regulators.

Meanwhile, Fosun Pharmaceutical announced that it had ordered 100 million doses of the COVID-19 vaccine developed by German drug company BioNTech, which will arrive in China in 2021. BioNTech has partnered with Pfizer to supply vaccines for the U.S. and EU markets, which were approved by their respective regulators, but the vaccine developed for the China market is still in Phase II trial.